Stephens raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $35 from $4 and keeps an Overweight rating on the shares. The price target increase reflects the recent 1-for-20 reverse stock split that went into effect on June 17, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.